FormsNet3 - Blank Form


 
 
Sequence Number    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type:  (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product Type (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with 115.

 
 
1  What was the date of diagnosis of bone or soft tissue Sarcoma? __ __ __ __ - __ __- __ __  

 
2  On the CIBMTR Form 2000 - Recipient Baseline Data, was the primary disease for which the HSCT was performed (question9) either "bone sarcoma (excluding Ewing family 

tumors)" (solid tumors option 10) or "soft tissue sarcoma (excluding Ewing family tumors)" (solid tumors option 21)? 

    
 nmlkji

yes  
 nmlkji

no  

 
 
3  Specify bone or soft tissue sarcoma:    

 
 

4  Primary site of sarcoma at diagnosis: (check only one)

    
 nmlkji

calcaneus  

 nmlkji
femur  

 nmlkji
fibula  

 nmlkji
humerus  

 nmlkji
metacarpal  

 nmlkji
metatarsal  

 nmlkji
multifocal  

 nmlkji
patella  

 nmlkji
pelvis  

 nmlkji
radius  

 nmlkji
rib  

 nmlkji
scapula  

 nmlkji
skull  

  Key Fields 

Disease Assessment at Diagnosis Questions: 1 - 76

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 9



 nmlkji
sternum  

 nmlkji
tibia  

 nmlkji
ulna  

 nmlkji
vertebra  

 nmlkji
other bone location  

 nmlkji
abdominal wall  

 nmlkji
buttock  

 nmlkji
Chest wall  

 nmlkji
foot  

 nmlkji
gastrointestinal  

 nmlkji
genitourinary  

 nmlkji
great vessels  

 nmlkji
gynecologic  

 nmlkji
hand  

 nmlkji
head and neck  

 nmlkji
heart  

 nmlkji
lower arm  

 nmlkji
lower leg  

 nmlkji
lung / pleura  

 nmlkji
Mediastinum  

 nmlkji
retroperitoneum  

 nmlkji
upper arm  

 nmlkji
upper leg  

 nmlkji
other viscera  

 nmlkji
other soft tissue location  

 
 
5  Specify multifocal:    

 
 
6  Specify other bone location:    

 
 
7  Specify other viscera:    

 
 
8  Specify other soft tissue location:    

  
 
9  What were the two largest dimensions of tumor mass at

diagnosis? 
   X 

 
.    cm 

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 9



 
 

10  Tumor mass was assessed by:

    
 nmlkji

apparent by palpation  

 nmlkji
apparent by visualization  

 nmlkji
plain film / x-ray without contrast  

 nmlkji
plain film / x-ray with contrast  

 nmlkji
CT scan  

 nmlkji
MRI scan  

 nmlkji
radioisotope scan  

 nmlkji
ultrasound  

 nmlkji
Other method  

 nmlkji
Unknown  

 
 
11  Specify assessment method:    

 
 

12  (For soft-tissue sarcoma only) What was the soft-tissue sarcoma grade at diagnosis?

    
 nmlkji

low  
 nmlkji

intermediate  
 nmlkji

high  
 nmlkji

Unknown  

 
 

13  Were metastases present at diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the site(s) of metastases at diagnosis: 
 

14  Abdominal - diffuse

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

15  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

16  Central nervous system (CNS)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

17  Liver

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

18  Lungs

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

19  Lymph nodes - distant

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

20  Lymph nodes - regional

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

21  Skin

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

22  Other site:

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
23  Specify site:    

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 9



 
24  On the CIBMTR Form 2000 - Recipient Baseline Data, was there a history of malignancy other than the primary disease for which this HSCT is being performed (question 22, 

answered "yes")? 

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify any treatment(s) given for the other malignancy: 
 

25  Chemotherapy

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

26  Radiation

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

27  Other treatment

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
28  Specify treatment    

 
 

29  Was a cytogenetic analysis of the tumor mass performed at any time?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

30  Results of tests at diagnosis:

    
 nmlkji

Yes abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

 

Specify Cytogenetic abnormalities identified at diagnosis: 

Translocation 

 
31  t(1;13)

    
 nmlkji

yes  
 nmlkji

no  

 
 

32  t(1;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

33  t(2;13)

    
 nmlkji

yes  
 nmlkji

no  

 
 

34  t(7;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

35  t(7;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

36  t(11;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

37  t(12;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

38  t(12;15)

    
 nmlkji

yes  
 nmlkji

no  

 
 

39  t(12;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

40  t(12;19)

    
 nmlkji

yes  
 nmlkji

no  

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 9



 
 

41  t(12;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

42  t(13;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

43  t(17;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

44  t(21;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

45  t(X;17)

    
 nmlkji

yes  
 nmlkji

no  

 
 

46  t(X;18)

    
 nmlkji

yes  
 nmlkji

no  

 

Deletion 
 

47  del(16q) / 16q-

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  del (17q) / 17q-

    
 nmlkji

yes  
 nmlkji

no  

 

Insertion 
 

49  ins(19p) / 19p+

    
 nmlkji

yes  
 nmlkji

no  

 

Other 
 

50  complex (>=3 distinct abnormalities)

    
 nmlkji

yes  
 nmlkji

no  

 
 

51  other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 
 
52  specify other abnormality:    

 
 

53  Results of tests after diagnosis to prior to the preparative regimen:

    
 nmlkji

Yes abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities on any tests after diagnosis and before the preparative regimen  

 

Specify cytogenetic abnormalities identified at any test result between diagnosis and preparative regimen 

Translocation 

 
54  t(1;13)

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  t(1;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  t(2;13)

    
 nmlkji

yes  
 nmlkji

no  

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 9



 
 

57  t(7;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  t(7;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

59  t(11;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

60  t(12;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

61  t(12;15)

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  t(12;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  t(12;19)

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  t(12;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

65  t(13;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

66  t(17;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

67  t(21;22)

    
 nmlkji

yes  
 nmlkji

no  

 
 

68  t(X;17)

    
 nmlkji

yes  
 nmlkji

no  

 
 

69  t(X;18)

    
 nmlkji

yes  
 nmlkji

no  

 

Deletion 
 

70  del(16q) / 16q-

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  del(17q) / 17q-

    
 nmlkji

yes  
 nmlkji

no  

 

Insertion 
 

72  ins(19p) / 19p+

    
 nmlkji

yes  
 nmlkji

no  

 

Other 
 

73  complex (>=3 distinct abnormalities)

    
 nmlkji

yes  
 nmlkji

no  

 
 

74  other abnormality

    
 nmlkji

yes  
 nmlkji

no  

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 9



 
 
75  specify other abnormality:    

 
 

76  Is a copy of the cytogenetic or FISH report attached?

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Was therapy given (including surgery and neo-adjuvant or adjuvant therapy) between diagnosis and the start of the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  

 

Line of Therapy 
 

78  Systemic Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
79  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
80  Date therapy stopped: __ __ __ __ - __ __- __ __  

  
 
81  Number of cycles    

 
  

gfedcb
Unknown/not applicable

 
 

82  Cisplatin (Platinol, CDDP)

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  cyclophosphamide (Cytoxan)

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  dactinomycin (Actinomycin D)

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  dacarbazine (DTIC)

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  Doxorubicin (Adriamycin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  etopside (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  Ifosfamide (Ifex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

89  imatinib (Gleevec)

    
 nmlkji

yes  
 nmlkji

no  

 
 

90  melphalan (L-PAM, Alkeran)

    
 nmlkji

yes  
 nmlkji

no  

 
 

91  sunitinib (Sutent, SU11248)

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  topotecan (Hycamtin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Vincristine (VCR, Oncovin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Other systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
95  Specify other therapy:    

  Pre-HSCT Treatment for Sarcoma Questions: 77 - 114

  Lines of Therapy (1) Questions: 78 - 114 

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 9



 
 

96  Radiation Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
97  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
98  Date therapy stopped: __ __ __ __ - __ __- __ __  

 
 

99  Local / regional

    
 nmlkji

yes  
 nmlkji

no  

 
 
100  Specify total dose    cGy (rads) 

 
 

101  Sites of non-contiguous metastases

    
 nmlkji

yes  
 nmlkji

no  

 
 
102  Specify total dose    cGy (rads) 

 
 

103  Other radiation therapy site

    
 nmlkji

yes  
 nmlkji

no  

 
 
104  Specify other radiation site    

 
 
105  Specify total dose    cGy (rads) 

 
 

106  Surgical Biopsy/Resection:

    
 nmlkji

yes  
 nmlkji

no  

 
 
107  Date of surgery: __ __ __ __ - __ __- __ __  

 
 

108  Type of surgery

      

 
 
109  Specify other surgery    

 
 

110  Site of surgery:

    
 nmlkji

primary lesion  
 nmlkji

metastatic lesion  
 nmlkji

Both  

 
111  Best Response to Line of Therapy: (see definitions on page 5)

    
 nmlkji

CR  (CR) - disappearance of all target lesions for a period of at least one month 

 nmlkji
CRU  (CRU) - complete response with persistent imaging abnormalities of unknown significance 

 nmlkji
PR  (PR) - at least 30% decrease in the sum of the longest diameter of measured lesions (target lesions) taking as reference the baseline sum of longest diameters 

 nmlkji
SD  (SD) - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameters since 

the treatment started  

 nmlkji
PD  (PD) - at least a 20% increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum of the longest 

diameters recorded since the treatment started or the appearance of one or more new lesions  

 nmlkji
NA  (Not assessed) 

 
 
112  Date response evaluated: __ __ __ __ - __ __- __ __  

 
 

113  Did disease relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 
114  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 
 

115  Serum alkaline phosphatase:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
116  .    

 
.

 nmlkji
IU/L  

 nmlkji
µkat/L  

 
 
117  Upper limit of normal for alkaline phosphatase:    

  Laboratory Studies Prior to the Start of the Preparative Regimen Questions: 115 - 117

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 9



 
 

118  What was the disease status at the last evaluation prior to the preparative regimen? (see definitions above)

    
 nmlkji

CR  
 nmlkji

CRU  
 nmlkji

PR  
 nmlkji

SD  
 nmlkji

PD  
 nmlkji

NA  
 nmlkji

Unknown  

 
 
119  Specify reason:    

 
 
120  Date of the most recent assessment for disease status prior to the preparative regimen: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

  Disease Status at the Last Assessment Prior to the Start of the Preparative Regimen Questions: 118 - 120

Form 2024 R2.0: Sarcoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2024 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 9